Journal
JOURNAL OF COMPUTATIONAL BIOLOGY
Volume 26, Issue 10, Pages 1177-1190Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/cmb.2019.0062
Keywords
Helicobacter pylori; in silico; multiepitope; oral vaccine; reverse vaccinology
Categories
Funding
- Unidad de Odontologia Integral y Especialidades of Centro de Investigacion y Desarrollo en Ciencias de la Salud (UOIE-CIDICS)
- Laboratorio de Inmunologia y Virologia (LIV) of School of Biological Sciences (FCB-UANL)
- Consejo Nacional de Ciencia y Tecnologia (CONACYT-Mexico) [252534, 251475, 578753]
Ask authors/readers for more resources
Helicobacter pylori is an infectious agent that colonizes the gastric mucosa of half of the population worldwide. This bacterium has been recognized as belonging to group 1 carcinogen by the World Health Organization for the role in development of gastritis, peptic ulcers, and cancer. Due to the increase in resistance to antibiotics used in the anti-H. pylori therapy, the development of an effective vaccine is an alternative of great interest, which remains a challenge. Therefore, a rational, strategic, and efficient vaccine design against H. pylori is necessary where the use of the most current bioinformatics tools could help achieve it. In this study, immunoinformatics approach was used to design a novel multiepitope oral vaccine against H. pylori. Our multiepitope vaccine is composed of cholera toxin subunit B (CTB) that is used as a mucosal adjuvant to enhance vaccine immunogenicity for oral immunization. CTB fused to 11 epitopes predicted of pathogenic (UreB(170-189), VacA(459-478), CagA(1103-1122), GGT(106-126), NapA(30-44), and OipA(211-230)) and colonization (HpaA(33-52), FlaA(487-506), FecA(437-456), BabA(129-149), and SabA(540-559)) proteins from H. pylori. CKS9 peptide (CKSTHPLSC) targets epithelial microfold cells to enhance vaccine uptake from the gut barrier. All sequences were joined to each other by proper linkers. The vaccine was modeled and validated to achieve a high-quality three-dimensional structure. The vaccine design was evaluated as nonallergenic, antigenic, soluble, and with an appropriate molecular weight and isoelectric point. Our results suggest that our newly designed vaccine could serve as a promising anti-H. pylori vaccine candidate.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available